Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.
Upadacitinib retreatment was safe and effective in patients who had treatment withdrawn.
Clinically significant improvements observed in skin symptoms, itch, and sleep disturbance with baricitinib in adults with moderate to severe AD with comorbid atopic conditions.
Dupilumab monotherapy or with concurrent TCS shown to significantly improve signs, symptoms, and quality of life in patients with erythrodermic AD in multiple randomized, placebo-controlled, double-blinded trials.
Severe atopic dermatitis was significantly improved for children aged ≥ 6 to < 12 years with dupilumab vs placebo.
Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.